// App-Quantinova.ai

3500 : Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Researchers

Presenter

  • Thierry Andre

Principal Investigators

  • Tae Won Kim

  • Benny Vittrup Jensen

  • Lars Henrik Jensen

  • Cornelis J. A. Punt

  • Denis Michel Smith

  • Rocio Garcia-Carbonero

  • Julia Alcaide

  • Peter Gibbs

  • Christelle De La Fouchardiere

  • Fernando Rivera

  • Elena Elez

  • Johanna C. Bendell

  • Dung T. Le

  • Takayuki Yoshino

  • Wen Yan Zhong

  • David R. Fogelman

  • Patricia Marinello

  • Luis A. Diaz

Medical Centers

  • Sorbonne University, Hôpital Saint-Antoine,Paris,France

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Herlev Hospital/ Gentofte Hospital, Herlev, Denmark

  • University Hospital of Southern Denmark

  • Vejle, Denmark

  • Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

  • Pellegin University Hospital, Bordeaux, France

  • Hospital Universitario 12 de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain

  • Hospital Regional Universitario de Malaga, Malaga, Spain

  • Western Health, Saint Albans, Australia

  • Centre Leon Berard, Lyon, France

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • National Cancer Center, EPOC, Chiba, Japan

  • MSD China

  • shanghai, China

  • Merck & Co., Inc., Kenilworth, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • France

  • United Kingdom

  • Denmark

  • Netherlands

  • Spain

  • Australia

  • United States

  • Japan

  • China

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Microsatellite instability-high

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

  • Erbitux

  • mFOLFOX6

  • FOLFIRI

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT02563002

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved